• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Vascular Solutions CEO’s reputation precedes him

Vascular Solutions CEO’s reputation precedes him

May 7, 2010 By MedCity News

MedCity News logo

Thomas Lee

Howard Root wants you to know that he’s not an angry man. Really.

Yes, the CEO of Vascular Solutions Inc. (NSDQ:VASC) sued another company for product defamation (Vascular won $3.5 million), tangled with local reporters (not me, at least not yet), and threatened not to develop any new products with Minnesota doctors if the state passed a disclosure bill (the legislation died).

And yes, he says what he thinks (Root was a debater at University of Minnesota law school).

“You get put into a position when you come across as hostile,” Root said. “People think I yell when I use the same tone because the point is sharp. A lot of people in medical devices think that. I do get beat up for it.”

But Vascular has emerged in recent years as a successful maker of peripheral and coronary artery devices precisely because Root has shied away from confrontation. Almost obliterated by head-to-head competition with St. Jude Medical Inc. (NYSE:STJ) in 2001, the company shifted gears and introduced multiple “small” products in niche markets largely ignored by the big medical device manufacturers.

Last month, Vascular said its first-quarter revenue jumped 15 percent, to an all-time high of $18.2 million, compared to $15.8 million during the same period last year. Excluding the $3.5 million from the defamation lawsuit, profits grew 35 percent, to $1.27 million. Gross profit margins across all products lines was a whopping 66.7 percent.

“The company has a nice, profitable strategy,” said Ernest Andberg, an equity analyst with Feltl & Co. in Minneapolis. Out of all the emerging medical device companies he covers, Andberg said, Vascular displays the most consistent growth and profitability.

The company closed May 6 at $10.10 a share, about 47 percent higher than at this point in 2009. Andberg even thinks investors are undervaluing Vascular by a dollar or two a share.

Armed with $22.4 million in cash, Vascular is now looking to expand through acquisitions: Earlier this week, it paid $5.75 million to acquire two ultrasound-guided needle products from from Escalon Vascular Access Inc., a division of Escalon Medical Corp. (NSDQ:ESMC).

That the Vascular of today is shopping for assets is remarkable when you consider the company was on the verge of extinction nearly a decade ago. Back then the firm, which went public in 2000, was selling only one product: The Duett, a sealing device that stopped bleeding of the femoral artery during surgery. A year later, St. Jude acquired similar technology from Tyco and quickly grabbed 85 percent market share.

Root said the company faced a critical decision.

“We were locked into a minority [market] position,” he said. “I got one shot to make it. I couldn’t wait until we had the money.”

So the company expanded its portfolio by developing many products in small markets, such as varicose veins, bio-based anti-clotting devices and a variety of catheters, micro-inducer kits, snares and specialty guidewires. Vascular also targeted doctors like pediatric interventional cardiologists, even though there are only 100 such physicians in the world, Root said.

“The big companies will not do it,” he said. “You don’t pick a fight with a bruiser the first day of school. Better yet, pick a place where you don’t get beat up.”

Last November, Vascular launched its GuideLiner catheters, designed to help surgeons with deep intubations during procedures to unclog coronary arteries. The company also hopes to fix its Acolysis ultrasound thrombolysis system, which uses low frequency, high energy ultrasound to remove blood clots. Vascular paid $2 million for the technology in 2002 but technical problems hobbled the product, which is not yet approved for use in the U.S.

Root said Vascular has reached a point where it needs acquisitions to boost growth.

“We’re great innovators on products that won’t make us a lot of money,” Root said. “We do have to step up on scale.”

Vascular is looking for $5 million, $10 million, $20 million deals to acquire “orphans” — market-ready products neglected by other companies that need better sales and marketing. One of Root’s proudest feats is building a dedicated sales force.

“Having a dedicated sales force is huge,” Root said. “We get most of our ideas from 80 sales reps making 2,000 calls a week than consulting with doctors. The direct sales force is the only way I can get direct access” to customers.

Feltl’s Andberg said the orphan strategy makes sense in the short term, as long as the company generates enough cash to finance the deals. Vascular could get tied down with lawsuits, especially intellectual property disputes, he said.

Andberg would also like to see a succession plan at Vascular, since so much of the company’s fortunes rest with its CEO and founder. That could be a challenge, giving Root’s outsized, polarizing personality.

“People either love working for me or hate working for me,” Root said.

Filed Under: Business/Financial News, News Well Tagged With: vascularsolutions

In case you missed it

  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans
  • Clarius partners with ImaCor on handheld hemodynamic ultrasound tech
  • Withings appoints Elizabeth Coleon as chief marketing officer
  • Visby Medical raises $135M in expanded Series E
  • Boston Scientific to build new plant outside Atlanta
  • NovaXS unveils prototype for smart, needle-free drug delivery device
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
  • SpineX enrolls first patient in spinal neuromodulation technology trial
  • GE Healthcare’s Carescape ventilator battery recall is Class I

RSS From Medical Design & Outsourcing

  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
    Cardinal Health (NYSE: CAH) today started air delivery of pharmaceutical products and medical supplies via Zipline drone in North Carolina. San Francisco-based Zipline won FAA Part 135 air carrier certification for the long-range flights earlier this month. The company flew its first commercial deliveries on June 22 with an initial 16-nautical-mile flight. The flights starting… […]
  • Boston Centerless opens manufacturing plant in Indiana
    Boston Centerless announced today that it opened a second manufacturing plant in Fort Wayne, Indiana. Woburn, Massachusetts-based Boston Centerless said in a news release that the latest expansion for the supplier of precision ground bar materials for close tolerance CNC Swiss machining applications represents continued robust growth in key market segments in the Midwest and… […]
  • Dymax strikes new partnership with Quantum Systems
    Rapid curing materials and equipment manufacturer Dymax today announced a new sales partnership with Quantum Systems. Torrington, Connecticut-based Dymax said in a news release that Quantum, with its offices in Arizona as well as Sonora and Baja, Mexico, will focus its efforts on promoting and supporting the sales of Dymax light-curing solutions to the medical,… […]
  • Researchers develop wearable robotic exomuscle system
    ETH Zurich researchers have redefined the muscle shirt. Marie Georgarakis, a former doctoral student at ETH Zurich’s Sensory Motor Systems Lab, is the creator of the Myoshirt, a wearable, textile robotic device that helps users lift their arms and reach. A motorized cable works like an artificial tendon, directed by sensors and an algorithm to… […]
  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS